Rhythm Pharmaceuticals

The company's business model is centered on addressing rare genetic deficiencies that lead to life-threatening metabolic disorders. Rhythm's primary source of revenue is the global sale of its lead product, IMCIVREE® (setmelanotide). For the second quarter of 2025, the company reported net product revenue of $48.5 million from these global sales. The company's financial strategy includes significant investment in research and development (R&D) and selling, general, and administrative (SG&A) expenses to support its pipeline and commercial infrastructure.

Rhythm's core focus is on the melanocortin-4 receptor (MC4R) pathway, which is crucial for regulating hunger, caloric intake, and energy expenditure. Impairments in this pathway can cause rare diseases characterized by hyperphagia—a pathological, insatiable hunger—and severe obesity. The company's lead asset, IMCIVREE® (setmelanotide), is an MC4R agonist designed to restore signaling in this pathway. This precision medicine is approved by the U.S. Food and Drug Administration (FDA), the European Commission (EC), and the UK's Medicines & Healthcare Products Regulatory Agency (MHRA) for treating obesity and controlling hunger in patients with specific rare genetic disorders. The approved indications include Bardet-Biedl syndrome (BBS) and deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) in patients aged 2 and older. Beyond its commercial activities, Rhythm is advancing a broad clinical development program, exploring setmelanotide for other rare MC4R pathway diseases like hypothalamic obesity, and developing other investigational MC4R agonists, including bivamelagon and RM-718.